Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge

    Question

    Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge

    Direct answer

    Bristol Myers Squibb's portfolio transition showed measurable progress in Q2 2026, with top-line revenue hitting $12.9 billion and non-GAAP EPS surging 153% year-over-year. The performance has supported a 17% year-to-date gain in BMY shares. Crucially, the company's designated growth portfolio of newly launched oncology, immunology, and cardiovascular therapies grew 15% year-over-year, now representing nearly 60% of aggregate revenue. The rising contribution cushions the pharmaceutical major against revenue erosion from approaching patent expirations on mature franchise drugs.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-growth-portfolio-reaches-60-of-revenue-following-q2-eps-sur-ecc6ea

    EQUITY
    Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge
    Bristol Myers Squibb's portfolio transition showed measurable progress in Q2 2026, with top-line revenue hitting $12.9 billion and non-GAAP EPS surging 153% year-over-year. The performance has supported a 17% year-to-date gain in BMY shares. Crucially, the company's designated growth portfolio of newly launched oncology, immunology, and cardiovascular therapies grew 15% year-over-year, now representing nearly 60% of aggregate revenue. The rising contribution cushions the pharmaceutical major against revenue erosion from approaching patent expirations on mature franchise drugs.
    BMYABBV
    Impact
    66
    SEP 21
    SIG
    82%
    BMYABBV
    Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge
    Bristol Myers Squibb's portfolio transition showed measurable progress in Q2 2026, with top-line revenue hitting $12.9 billion and non-GAAP EPS surging 153% year-over-year. The performance has supported a 17% year-to-date gain in BMY shares. Crucially, the company's designated growth portfolio of newly launched oncology, immunology, and cardiovascular therapies grew 15% year-over-year, now representing nearly 60% of aggregate revenue. The rising contribution cushions the pharmaceutical major against revenue erosion from approaching patent expirations on mature franchise drugs.
    → A 15% expansion in new commercial therapies pushes growth portfolio revenue to 60% of mix, mitigating multiple contraction from legacy drug patent expirations on BMY.
    Impact
    Bristol Myers Squibb's portfolio transition showed measurable progress in Q2 2026, with top-line revenue hitting $12.9 billion and non-GAAP EPS surging 153% year-over-year. The performance has supported a 17% year-to-date gain in BMY shares. Crucially, the company's designated growth portfolio of newly launched oncology, immunology, and cardiovascular therapies grew 15% year-over-year, now representing nearly 60% of aggregate revenue. The rising contribution cushions the pharmaceutical major against revenue erosion from approaching patent expirations on mature franchise drugs.
    Affected
    BMYABBV
    Transmission
    A 15% expansion in new commercial therapies pushes growth portfolio revenue to 60% of mix, mitigating multiple contraction from legacy drug patent expirations on BMY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYpatent cliff revenue replacement and forward multiple re-ratingUp1-3mBMY Q2 revenue reached $12.9B with 153% EPS growth and growth portfolio reaching 60% of sales.
    ABBVlarge-cap biopharma loss-of-exclusivity replacement peer benchmarkingWatch1-3mPeer pharmaceutical companies navigating simultaneous post-patent transition cycles.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month